

Peter A Van Dam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6790522/publications.pdf>

Version: 2024-02-01

96
papers

5,133
citations

117625

34
h-index

91884

69
g-index

98
all docs

98
docs citations

98
times ranked

7007
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of a new online cognitive assessment tool in breast cancer survivors with cognitive impairment: a prospective cohort study. <i>Supportive Care in Cancer</i> , 2022, 30, 21-31.	2.2	3
2	Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer. <i>European Journal of Cancer</i> , 2022, 163, 177-179.	2.8	26
3	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. , 2022, 236, 108107.		22
4	Abstract P1-04-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer. <i>Cancer Research</i> , 2022, 82, P1-04-07-P1-04-07.	0.9	1
5	Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments. <i>Pharmaceutics</i> , 2022, 14, 939.	4.5	4
6	AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 859-867.	2.2	14
7	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 987.	3.7	38
8	Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1807.	4.1	8
9	The tele-transition of toxicity management in routine oncology care during the severe acute respiratory syndrome (SARS-CoV-2) pandemic. <i>British Journal of Cancer</i> , 2021, 124, 1366-1372.	6.4	5
10	Immuno-PET Molecular Imaging of RANKL in Cancer. <i>Cancers</i> , 2021, 13, 2166.	3.7	3
11	Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. <i>European Journal of Cancer</i> , 2021, 148, 328-339.	2.8	14
12	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
13	The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 4656.	3.7	10
14	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Oncimmunology</i> , 2021, 10, 1929724.	4.6	22
15	Meeting the Challenges in Cancer Care Management During the SARS-Cov-2 Pandemic: A Retrospective Analysis. <i>Cancer Control</i> , 2021, 28, 107327482110452.	1.8	4
16	Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients. <i>Cancers</i> , 2021, 13, 5718.	3.7	10
17	The potential and controversy of targeting STAT family members in cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 41-56.	9.6	226
18	Triple-negative breast cancer—Role of immunology: A systemic review. <i>Breast Journal</i> , 2020, 26, 995-999.	1.0	36

#	ARTICLE	IF	CITATIONS
19	The immunologic aspects in hormone receptor positive breast cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100207.	1.7	4
20	SARS-CoV-2 and cancer: Are they really partners in crime?. <i>Cancer Treatment Reviews</i> , 2020, 89, 102068.	7.7	60
21	Acceptability of quality indicators for the management of endometrial, cervical and ovarian cancer: results of an online survey. <i>BMC Women's Health</i> , 2020, 20, 151.	2.0	2
22	Oncological outcome, postoperative complications, and mammographic changes after intraoperative radiotherapy with electrons (IOERT) as a boost in a large single-institution cohort of breast cancer patients. <i>Breast Journal</i> , 2020, 26, 1937-1945.	1.0	4
23	HIPEC in advanced epithelial ovarian cancer: why is there controversy?. <i>Current Opinion in Oncology</i> , 2020, 32, 451-458.	2.4	6
24	High mortality of cancer patients in times of SARS-CoV-2: Do not generalize!. <i>European Journal of Cancer</i> , 2020, 138, 225-227.	2.8	7
25	A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial. <i>Breast</i> , 2020, 53, 23-32.	2.2	23
26	Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform. <i>ESMO Open</i> , 2020, 5, e000817.	4.5	11
27	The art of obtaining a high yield of cell-free DNA from urine. <i>PLoS ONE</i> , 2020, 15, e0231058.	2.5	39
28	Inflammatory breast cancer cells are characterized by abrogated TGF β 1-dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 385-395.	2.5	18
29	The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 53-62.	1.6	4
30	The use of buparlisib as a radiosensitizer: What about toxicity?. <i>European Journal of Cancer</i> , 2019, 119, 194-195.	2.8	2
31	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apolisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	7.0	76
32	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2183.	4.1	22
33	The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1). <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100123.	1.7	15
34	RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 85-91.	4.4	57
35	Quality indicators for the management of endometrial, cervical and ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 528-537.	1.0	15
36	Bone metastases in the era of targeted treatments: insights from molecular biology. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 98-111.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Potential new biomarkers for squamous carcinoma of the uterine cervix. <i>ESMO Open</i> , 2018, 3, e000352.	4.5	18
38	Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. <i>ESMO Open</i> , 2018, 3, e000398.	4.5	79
39	FGFR a promising druggable target in cancer: Molecular biology and new drugs. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 256-267.	4.4	167
40	Neoadjuvant trials can accelerate research on novel systemic treatment modalities in cancer of the uterine cervix. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2245-2247.	1.0	5
41	The role of Nuclear Factor-kappa B signaling in human cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 141-150.	4.4	200
42	In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment. <i>Oncotarget</i> , 2016, 7, 2780-2795.	1.8	20
43	Decreased expression of ABAT and STC2 hallmarks ER α -positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015, 9, 1218-1233.	4.6	64
44	A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples. <i>PLoS ONE</i> , 2014, 9, e89262.	2.5	13
45	Contribution of ER and NF- κ B to endocrine resistance in inflammatory breast cancer. <i>Breast Cancer Management</i> , 2014, 3, 53-61.	0.2	1
46	Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. <i>Breast</i> , 2014, 23, 453-459.	2.2	15
47	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 557-570.	2.5	23
48	Genomic profiling of inflammatory breast cancer: A review. <i>Breast</i> , 2014, 23, 538-545.	2.2	46
49	A dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002-2010. <i>World Journal of Surgical Oncology</i> , 2013, 11, 70.	1.9	27
50	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. <i>Clinical Cancer Research</i> , 2013, 19, 4685-4696.	7.0	130
51	The interaction between ER and NF- κ B in resistance to endocrine therapy. <i>Breast Cancer Research</i> , 2012, 14, 212.	5.0	89
52	VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 805-808.	2.4	3
53	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3600-3618.	7.0	207
54	Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma. <i>PLoS ONE</i> , 2011, 6, e22469.	2.5	24

#	ARTICLE	IF	CITATIONS
55	Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination. <i>PLoS ONE</i> , 2010, 5, e12616.	2.5	74
56	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2630-2637.	1.6	582
57	The rationale for mTOR inhibition in epithelial ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1885-1891.	4.1	15
58	Fulvestrant (Faslodex, F) in advanced breast cancer: clinical experience from a Belgian cooperative study. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 59-65.	2.5	19
59	Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. <i>Fertility and Sterility</i> , 2008, 90, 17-22.	1.0	112
60	Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7452-7460.	7.0	28
61	Gene Expression Profiles Associated with the Presence of a Fibrotic Focus and the Growth Pattern in Lymph Node-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2944-2952.	7.0	35
62	Increased Sentinel Lymph Node Lymphangiogenesis is Associated with Nonsentinel Axillary Lymph Node Involvement in Breast Cancer Patients with a Positive Sentinel Node. <i>Clinical Cancer Research</i> , 2007, 13, 5391-5397.	7.0	91
63	Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 13-23.	3.3	23
64	Nuclear Factor- κ B Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor- κ B DNA-Binding. <i>Clinical Cancer Research</i> , 2006, 12, 3249-3256.	7.0	101
65	Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: Do they have any significance?. <i>Maturitas</i> , 2006, 55, 94-95.	2.4	5
66	Inflammatory breast cancer: current understanding. <i>Current Opinion in Oncology</i> , 2006, 18, 563-571.	2.4	36
67	Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer. <i>Obstetrics and Gynecology</i> , 2006, 107, 207-208.	2.4	5
68	Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 219-228.	2.5	87
69	Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 243-255.	2.5	105
70	Prognostic Significance of Disseminated Tumor Cells as Detected by Quantitative Real-Time Reverse-Transcriptase Polymerase Chain Reaction in Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 146-152.	2.4	27
71	Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer?. <i>Current Opinion in Oncology</i> , 2005, 17, 551-558.	2.4	23
72	Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 237-246.	2.5	104

#	ARTICLE	IF	CITATIONS
73	Tumor Lymphangiogenesis in Inflammatory Breast Carcinoma: A Histomorphometric Study. <i>Clinical Cancer Research</i> , 2005, 11, 7637-7642.	7.0	152
74	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. <i>Clinical Cancer Research</i> , 2004, 10, 7965-7971.	7.0	215
75	Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival. <i>Clinical Cancer Research</i> , 2004, 10, 7157-7162.	7.0	309
76	Sentinel node detection in patients with vaginal carcinoma. <i>Gynecologic Oncology</i> , 2004, 92, 89-92.	1.4	37
77	Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2003, 103, 642-646.	5.1	365
78	Sentinel Node Metastasis in the Groin Detected by Technetium-Labeled Nanocolloid in a Patient with Cervical Cancer. <i>Gynecologic Oncology</i> , 2002, 86, 358-360.	1.4	23
79	Interval debulking surgery: An alternative for primary surgical debulking?. <i>Journal of Surgical Oncology</i> , 2000, 19, 49-53.	1.4	33
80	Epithelioid Sarcoma of the Vulva. <i>Gynecologic Oncology</i> , 1999, 73, 160-164.	1.4	40
81	Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced?. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 181, 536-541.	1.3	128
82	Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 181, 554-559.	1.3	21
83	Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 178, 113-117.	1.3	49
84	Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 165-172.	2.5	50
85	Editorial. <i>Gynecologic Oncology</i> , 1996, 62, 322-323.	1.4	1
86	Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: A prospective randomized trial. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 174, 943-950.	1.3	37
87	Study of numerical aberrations of chromosome 1 by fluorescent in situ hybridization and DNA content by densitometric analysis on (pre)-malignant cervical lesions. <i>The Histochemical Journal</i> , 1995, 27, 24-34.	0.6	27
88	Primary Extruterine Müllerian Adenosarcoma of the Peritoneum. <i>Gynecologic Oncology</i> , 1995, 57, 126-130.	1.4	15
89	Carcinoma in episiotomy scars. <i>Gynecologic Oncology</i> , 1992, 44, 96-100.	1.4	39
90	Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. <i>Gynecologic Oncology</i> , 1991, 42, 256-264.	1.4	43

#	ARTICLE	IF	CITATIONS
91	Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2. <i>Cancer</i> , 1991, 68, 169-177.	4.1	12
92	Prostacyclin/Thromboxane Ratio in Human Breast Cancer. <i>Tumor Biology</i> , 1991, 12, 261-266.	1.8	8
93	Retroperitoneal Soft Tissue Sarcomas. <i>Obstetrical and Gynecological Survey</i> , 1990, 45, 670-682.	0.4	25
94	The use of rectus abdominis myocutaneous flaps following excision of vulvar cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1990, 97, 1020-1025.	2.3	35
95	Flow cytometric quantitation of tumor-associated antigens in solid tumors. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 163, 698-699.	1.3	5
96	Application of ultrasound in the diagnosis of heterotopic pregnancy—a review of the literature. <i>Journal of Clinical Ultrasound</i> , 1988, 16, 159-165.	0.8	27